+ 44 (0)20 8332 2588

Phase I is the lifeblood or new medicines. The UK’s Phase I representative body,

Asthma is a chronic inflammatory disorder of the airways

Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.

There have been hundreds of thousands of deaths from COVID-19

The sudden imposition of remote working in response to the 2020 COVID-19

Phenotype-specific omic expression patterns in people with frailty could provid

The comparison of the DPP4 (dipeptidyl peptidase 4) SARS-CoV-2

In this case the plan is a paradigm shift in the way we will manage

The latest issue of Journal Frontiers in Pharmacology has just published

I'm sure that everyone works hard and tries to do their best.

Our publication on effectiveness of a multimodal intervention

ive years ago I was lucky enough to be involved in a project that resulted in publications

Because new biologic treatments for asthma can be expensive and cause side effects,

The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)

The EUropean Federation for Exploratory MEdicines Development (EUFEMED

We all get them, some of us more than 10 a day, emails from journals

Our publication on the potential benefits of bariatric surgery

The first publication to come out of our UK Refractory Asthma

Our publication on sarcoidosis, a multisystem inflammatory disease

Our publication on new therapies in the management of type 2 diabetes mellitus

ur publication on new therapies to reduce low-density

Our publication on the use of cardiovascular medication in women and continence

The progression of atherosclerosis, which is responsible for coronary heart disease

Today we had our manuscript on the pre-protein convertase subtilisin kexin (PCSK)-9

Epidemiological data suggest that at two in five of us will experience